Dorobisz, K.; Dorobisz, T.; Pazdro-Zastawny, K.
Reply to Itagaki et al. Comment on “Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416”. Cancers 2024, 16, 3952.
https://doi.org/10.3390/cancers16233952
AMA Style
Dorobisz K, Dorobisz T, Pazdro-Zastawny K.
Reply to Itagaki et al. Comment on “Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416”. Cancers. 2024; 16(23):3952.
https://doi.org/10.3390/cancers16233952
Chicago/Turabian Style
Dorobisz, Karolina, Tadeusz Dorobisz, and Katarzyna Pazdro-Zastawny.
2024. "Reply to Itagaki et al. Comment on “Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416”" Cancers 16, no. 23: 3952.
https://doi.org/10.3390/cancers16233952
APA Style
Dorobisz, K., Dorobisz, T., & Pazdro-Zastawny, K.
(2024). Reply to Itagaki et al. Comment on “Dorobisz et al. Assessment of Prognostic Factors, Clinical Features Including the Microbiome, and Treatment Outcomes in Patients with Cancer of Unknown Primary Site. Cancers 2024, 16, 3416”. Cancers, 16(23), 3952.
https://doi.org/10.3390/cancers16233952